SSY GROUP (02005.HK) -0.060 (-2.542%) Short selling $3.46M; Ratio 35.523% announced that Shijiazhuang No. 4, a wholly-owned subsidiary of the Company, entered into a letter of intent (LOI) with Longhai Pharma in relation to a possible collaboration in respect of four biosimilar drugs, being Ustekinumab, Dupilumab, Aflibercept injection and Evolocumab. (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-08 16:25.)
AASTOCKS Financial News